RxPONDER clinical trial key findings

presented at San Antonio Breast Cancer Symposium

December 8-11, 2020


The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX®test


RxPONDER clinical trial key findings*


  • The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 significantly benefit from chemotherapy
  • RxPONDER study results are expected to be practice-changing for postmenopausal N1 HR+, HER2-, early breast cancer patients

* Kalinsky et al. San Antonio Breast Cancer Symposium 2020, GS3-00

RxPONDER clinical trial design


  • RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
  • The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score® result 0-25


Please see the press release here



Exact Sciences Lunch Symposium

Yes or No? Answering chemotherapy and endocrine therapy questions through a case-based discussion with the Oncotype DX test

Speakers


Dr. Alison Stopeck
Alison Stopeck, MD
Stony Brook Cancer Center
Dr. Jeremy Force
Jeremy Force, DO
Duke Cancer Center
Dr. Christy Russell
Christy Russell, MD
Exact Sciences

Video recording will soon be available here


YES NO Chemotherapy image
This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not those of the San Antonio Breast Cancer Symposium® (SABCS®).
YES NO Chemotherapy image
This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not those of the San Antonio Breast Cancer Symposium® (SABCS®).


Other presentations of interest on
the Oncotype DX® Breast Recurrence Score Test


SWOG S1007: adjuvant trial randomized ER+ patients who had a Recurrence Score <25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy

Read the press release here

A prospective multicenter study evaluating the impact of the 21-gene Breast Recurrence Score upon physician treatment decision and cost in N+ breast cancer patients in Quebec
Abstract | Hassan

An analysis of the clinical and economic impact of the 21-gene Recurrence Score in invasive lobular early-stage breast cancer in Ireland
Abstract | Tharmabala

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Frist efficacy results from the ADAPT HR+/HER2- trial
Abstract | Harbeck

Neoadjuvant nab-paciltaxel weekly vs dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC: results from the neoadjuvant part of ADAPT HR+/HER2- trial
Abstract | Kuemmel

Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
Abstract | Sparano

Read the press release here

ADAPTlate: A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant ER versus standard adjuvant ER in (clinical or genomic) high risk, HR+/HER2- early breast cancer
Abstract | Gluz

The feasibility of obtaining Oncotype DX Breast Recurrence Score results from the metastatic sites of patients with HR+ metastatic breast cancer
Abstract | Gemmill

Can genomic profiling eliminate the need for SLNB in ER+, T1-2 breast cancer
Abstract | Jackson

Contact Us

 Get in Touch
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.